Bimekizumab Anti-Human IL17A/IL-17F Recombinant Antibody,95.00%
产品编号：Bellancom-P99280| CAS NO：1418205-77-2
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，
Bimekizumab Anti-Human IL17A/IL-17F Recombinant Antibody
| 产品介绍 | Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) 是一种人源化单克隆抗体，可选择性中和 IL-17A 和 IL-17F。这两种细胞因子都能够促进成骨的人骨膜衍生细胞 (hPDC) 分化。因此，Bimekizumab 的应用，可以阻断炎症驱动的成骨分化。 |
|---|---|
| 生物活性 | Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation. |
| 体外研究 |
Bimekizumab (10 μg/mL; 1 h) results dual neutralisation of IL-17A and IL-17F, leads to osteocommitment of hPDCs by AS serum is suppressed. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. |
| 体内研究 | |
| 体内研究 | |
| 性状 | Liquid |
| 溶解性数据 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. |
| 参考文献 |
浙公网安备 33010802013016号